View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 26, 2020updated 12 Jul 2022 11:48am

Glenmark starts Phase III Favipiravir combination study for Covid-19

Glenmark Pharmaceuticals has launched a Phase III clinical trial to assess Favipiravir in combination with antiviral drug Umifenovir for the treatment of Covid-19 in India.

Glenmark Pharmaceuticals has launched a Phase III clinical trial to assess Favipiravir in combination with antiviral drug Umifenovir for the treatment of Covid-19 in India.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Earlier this month, Glenmark commenced a separate Phase III trial to assess favipiravir alone as a potential treatment for Covid-19 patients in the country.

Favipiravir and Umifenovir have unique mechanisms of action, and their combination is expected to improve efficacy by addressing high viral loads during the early stage of the disease.

Favipiravir has been approved in Japan since 2014 to treat new or re-emerging influenza virus infections. It inhibits viral replication by blocking RNA polymerase activity.

Meanwhile, Umifenovir is licensed in Russia and China for the treatment and prophylaxis of influenza A and B infections. It works by preventing the viral attachment to cells and has modulatory effects on the immune system, triggering interferon-production.

In-vitro, the drugs demonstrated the ability to inhibit viral infection and demonstrated efficacy in Covid-19 trials.

Glenmark Pharmaceuticals Clinical Development Global Specialty/Branded Portfolio vice-president and head Dr Monika Tandon said: “We consider Glenmark’s study will be pivotal in leading to identification of highly effective and safe treatments against Covid-19 in India.

“Beyond its many potential patient treatment benefits, we also hope the combination therapy will reduce infection risk amongst medical professionals and healthcare workers by reducing the duration of virus shedding from treated patients.”

The new Phase III study, named FAITH, will enrol 158 hospitalised patients with moderate Covid-19 infection. Participants will be given Favipiravir and Umifenovir or Favipiravir with standard supportive care.

The treatment duration is 14 days and patients will be discharged following clinical cure and two consecutive negative tests for Covid-19.

Results from the Phase III Favipiravir monotherapy study are expected by July or August this year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena